Expanding diagnostic testing for drug-resistant tuberculosis in high burden settings: a cost-effectiveness analysis
In high TB-burden countries, GeneXpert XDR is cost-effective as an additional DR-TB diagnostic test. tNGS is not cost-effective for routine clinical DR-TB testing but has potential for application to high-risk populations, especially with introduction of new TB treatment regimens.
Authors
- Francis A. Tablizo (ORCID: https://orcid.org/0009-0007-1392-3671)
- John Pastor Ansah (ORCID: https://orcid.org/0000-0001-9157-4218)
- Marya Getchell (ORCID: https://orcid.org/0000-0002-5831-4008)
- Ramon Basilio
- Dodge R. Lim (ORCID: https://orcid.org/0000-0002-6271-3861)
- David Bruce Matchar (ORCID: https://orcid.org/0000-0003-3020-2108)
- Carmen Corpuz
Institutions
- University of the Philippines System (PH)
- Department of Health (PH)
- SingHealth (SG)
- Duke University (US)
- Research Institute for Tropical Medicine (PH)
- Duke-NUS Medical School (SG)
- Case Western Reserve University (US)
Publication Details
- Journal
- BMC Public Health
- Published
- 2025-11-05
- DOI
- https://doi.org/10.1186/s12889-025-24934-z
- Primary Topic
- Tuberculosis Research and Epidemiology
- Type
- article
- Field-Weighted Citation Impact
- 0.00